AI Article Synopsis
- The study assessed the prevalence of mixed cryoglobulinemia (MC) among patients with chronic hepatitis C (CHC), finding it present in 27% of the evaluated patients.
- The research indicated that older age and the presence of cirrhosis were linked to a higher prevalence of MC, while no correlation was found with viral load or genotype.
- Treatment with interferon-alpha and ribavirin yielded similar sustained virological response rates in patients with and without MC.
Article Abstract
Introduction: The main extra-hepatic manifestation of hepatitis C is mixed cryoglobulinemia (MC). The aim of this study was to evaluate its prevalence among patients with chronic hepatitis C (CHC), to correlate its presence to host and virological variables and to the response to combined therapy with interferon-alpha and ribavirin.
Casuistic And Methods: 202 CHC naive patients (136 with chronic hepatitis and 66 with cirrhosis) were consecutively evaluated for the presence of cryoglobulins. Cryoprecipitates were characterized by immunoelectrophoresis and classified according to the Brouet's criteria.
Results: The prevalence of MC was 27% (54/202), and 24% of them (13/54) showed major clinical manifestation of the disease. Even though type III MC was more frequent (78%), symptomatic MC was more common in type II MC. The presence of cirrhosis (RR=2.073; IC95%=1.029-4.179; p=0.041), and age of the patients (RR=1.035; IC95%=1.008-1.062; p=0.01) were independently associated with the presence of cryoglobulins. No relationship was found with viral load and genotype. 102 patients were treated with interferon alpha and ribavirin. Among these, 31 had MC. Sustained virological response (around 30%) was similar in patients with and without MC (p=0.971).
Conclusion: MC represents a prevalent complication in patients with CHC, specially older and cirrhotic patients. Only 24% of these patients show clinical manifestation of the disease, specially those with type II MC. The presence of MC did not affect the response to therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/s0036-46652007000200001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Nucleos(t)ide Analogs on Major Clinical Outcomes in Patients With Chronic Hepatitis B: A 10-Year French Nationwide Cohort Study.
Aliment Pharmacol Ther
December 2024
Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP, Paris, France.
Background: Conflicting results have been reported on the impact of tenofovir versus entecavir on liver-related outcomes.
Aims: To explore trends in clinical outcomes in chronic hepatitis B virus (HBV)-infected patients and compare the impact of tenofovir versus entecavir on the risk of hepatocellular carcinoma (HCC), liver transplantation (LT) and mortality.
Methods: We used the French National Health Insurance Databases (SNDS) to identify HBV-infected patients.
The effect and application of adiponectin in hepatic fibrosis.
Gastroenterol Rep (Oxf)
December 2024
Department of Laboratory Medicine, First Hospital of Jilin University, Changchun, Jilin, P. R. China.
Hepatic fibrosis, a degenerative liver lesion, significantly contributes to the deterioration and mortality among patients with chronic liver diseases. The condition arises from various factors including toxins, such as alcohol, infections like different types of viral hepatitis, and metabolic diseases. Currently, there are no effective treatments available for liver fibrosis.
View Article and Find Full Text PDFAmeliorating Effects of β-Myrcene, a Monoterpene in Many Plants, on Thioacetamide-Induced Acute Hepatic Encephalopathy in Rats.
Arch Razi Inst
June 2024
Department of Pharmacy Practice, P.E.S. College of Pharmacy, Rajiv Gandhi University of Health Sciences, Bangalore, India.
Hepatic encephalopathy (HE) is a clinical syndrome that can result from acute and chronic liver disorders, such as hepatitis, liver failure caused by alcohol or drugs, autoimmune diseases, metabolic diseases, cirrhosis, different types of tumors, and infections. This study aimed to investigate the effects of different doses of Beta-myrcene (β-myrcene) on the improvement of HE caused by thioacetamide (TAC) in male rats. To induce liver failure and acute damage in the studied animals, TAC was administered to rats at a dose of 100 mg/kg of body weight through an intraperitoneal (IP) injection with 24-hour intervals for seven consecutive days.
View Article and Find Full Text PDFDr. Jekyll or Mr. Hyde: The multifaceted roles of miR-145-5p in human health and disease.
Noncoding RNA Res
April 2025
Department of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, 11200 SW 8th Street, Miami, FL 33199, USA.
MicroRNAs (miRNAs) are classified as small, non-coding RNAs that play crucial roles in diverse biological processes, including cellular development, differentiation, growth, and metabolism. MiRNAs regulate gene expression by recognizing complementary sequences within messenger RNA (mRNA) molecules. Recent studies have revealed that miR-145-5p functions as a tumor suppressor in several cancers, including lung, liver, and breast cancers.
View Article and Find Full Text PDFComparison of models to predict incident chronic liver disease: a systematic review and external validation in Chinese adults.
BMC Med
December 2024
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Beijing, 100191, China.
Background: Risk prediction models can identify individuals at high risk of chronic liver disease (CLD), but there is limited evidence on the performance of various models in diverse populations. We aimed to systematically review CLD prediction models, meta-analyze their performance, and externally validate them in 0.5 million Chinese adults in the China Kadoorie Biobank (CKB).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!